The trial of the first oral drug developed in Spain against COVID-19 is nearing completion


Paul Burton, our medical director

Moderna is working on new guidelines and doses for a COVID-19 vaccine, and on other applications of its mRNA technology.

Moderna “Spikevax” antiviral vaccine is the first mRNA platform-based product to hit the market. Photo: Luis Camacho.

Leave a Comment